Bath & Body Works, Inc. (NYSE:BBWI – Get Rating) CFO Wendy C. Arlin sold 6,000 shares of Bath & Body Works stock in a transaction dated Tuesday, April 19th. The shares were sold at an average price of $55.00, for a total transaction of $330,000.00. Following the completion of the transaction, the chief financial officer now directly owns 98,888 shares of the company’s stock, valued at $5,438,840. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Shares of NYSE BBWI traded up $1.26 during midday trading on Wednesday, reaching $56.83. The company’s stock had a trading volume of 6,135,019 shares, compared to its average volume of 4,503,807. The company has a 50 day moving average price of $50.46 and a 200 day moving average price of $61.31. Bath & Body Works, Inc. has a one year low of $44.17 and a one year high of $82.00. The company has a market cap of $13.55 billion, a price-to-earnings ratio of 11.59, a price-to-earnings-growth ratio of 1.23 and a beta of 1.76.
Bath & Body Works (NYSE:BBWI – Get Rating) last released its earnings results on Wednesday, February 23rd. The company reported $2.30 EPS for the quarter, topping analysts’ consensus estimates of $2.27 by $0.03. Bath & Body Works had a net margin of 14.13% and a negative return on equity of 115.32%. The business had revenue of $3.03 billion for the quarter, compared to the consensus estimate of $2.96 billion. During the same period in the previous year, the firm earned $1.96 EPS. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. Research analysts anticipate that Bath & Body Works, Inc. will post 4.59 EPS for the current year.
Several research analysts have recently commented on the stock. JPMorgan Chase & Co. decreased their price target on shares of Bath & Body Works from $105.00 to $81.00 and set an “overweight” rating for the company in a report on Thursday, February 24th. The Goldman Sachs Group raised shares of Bath & Body Works from a “buy” rating to a “conviction-buy” rating in a report on Wednesday, January 19th. Robert W. Baird decreased their price target on shares of Bath & Body Works from $90.00 to $75.00 in a report on Friday, February 25th. Deutsche Bank Aktiengesellschaft decreased their price target on shares of Bath & Body Works from $86.00 to $78.00 and set a “buy” rating for the company in a report on Thursday, February 24th. Finally, Zacks Investment Research lowered shares of Bath & Body Works from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 11th. Three research analysts have rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $78.89.
Large investors have recently added to or reduced their stakes in the stock. Lone Pine Capital LLC acquired a new position in shares of Bath & Body Works in the 3rd quarter valued at $1,531,646,000. BlackRock Inc. acquired a new position in shares of Bath & Body Works in the 3rd quarter valued at $1,184,238,000. Egerton Capital UK LLP acquired a new position in shares of Bath & Body Works in the 3rd quarter valued at $889,125,000. Steadfast Capital Management LP acquired a new stake in shares of Bath & Body Works during the 3rd quarter worth about $468,997,000. Finally, Primecap Management Co. CA acquired a new stake in shares of Bath & Body Works during the 3rd quarter worth about $382,655,000. Hedge funds and other institutional investors own 92.23% of the company’s stock.
About Bath & Body Works (Get Rating)
Bath & Body Works, Inc operates a specialty retailer of home fragrance, body care, and soaps and sanitizer products. The company sells its products under the Bath & Body Works, White Barn, and other brand names through specialty retail stores and websites located in the United States and Canada, as well as through international stores operated by partners under franchise, license, and wholesale arrangements.
- Get a free copy of the StockNews.com research report on Bath & Body Works (BBWI)
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
- Buy Haliburton On Post-Earnings Weakness
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.